Small cell lung cancer (SCLC) was highly malignant and lack effective treatment after the failure of radiotherapy and chemotherapy. Antiangiogenic therapy had shown a certain effect in advanced SCLC. Apatinib, a new potent oral small-molecule tyrosine kinase inhibitor targeting the intracellular domain of vascular endothelial growth factor receptor 2 (VEGFR-2), showed the effect of anti-angiogenesis. However, the efficacy in SCLC was rarely reported. We reported 1 case of advanced SCLC with Gilbert syndrome, the patient received Apatinib after the failure of 4 lines of chemotherapy, and achieved a partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 standard after one month. The progression-free survival (PFS) was 5 months. Apatinib was well tolerated except recurrent grade 3 hyperbilirubinemia because of the metabolic disorder of Bilirubin. Salvage treatment with Apatinib for advanced SCLC deserved further exploration. .
【中文题目：阿帕替尼用于小细胞肺癌多线治疗后的挽救治疗】 【中文摘要：小细胞肺癌（small cell lung cancer, SCLC）恶性程度高，在放、化疗失败后缺乏有效治疗手段，抗血管生成治疗在晚期SCLC中表现出一定的疗效。阿帕替尼是一种口服小分子酪氨酸激酶抑制剂，通过抑制血管内皮生长因子受体2（vascular endothelial growth factor receptor 2, VEGFR-2）达到抗血管生成的作用，在SCLC上的应用报道较少。本文报道了1例合并有Gilbert综合征的SCLC患者，在4线化疗失败后接受了阿帕替尼的挽救治疗，1个月后达到部分缓解（partial remission, PR），最终获得了5个月的无进展生存时间。由于胆红素代谢障碍，该患者在阿帕替尼治疗过程中反复出现3级的高胆红素血症，余不良反应耐受良好。阿帕替尼在晚期SCLC挽救治疗中的作用值得进一步探索。 】 【中文关键词：小细胞肺癌；抗血管生成；阿帕替尼；Gilbert 综合征】.
Keywords: Angiogenesis; Apatinib; Gilbert syndrome; Small cell lung cancer.